Cargando…
ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable. Whether the administration of immune checkpoint inhibitor (ICI) therapy is suitable for ROS 1 fusion NSCLCs or after the development...
Autores principales: | Cai, Liangliang, Duan, Jianchun, Qian, Li, Wang, Zhijie, Wang, Shuhang, Li, Sini, Wang, Chao, Zhao, Jie, Zhang, Xue, Bai, Hua, Wang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723923/ https://www.ncbi.nlm.nih.gov/pubmed/33324391 http://dx.doi.org/10.3389/fimmu.2020.527750 |
Ejemplares similares
-
Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
por: Huang, Richard S.P., et al.
Publicado: (2020) -
HGG-13. ONCOGENIC STAT3 AND SHP2 ACTIVATION IN ROS1-FUSION DRIVEN INFANT-TYPE HEMISPHERIC GLIOMAS
por: Postlmayr, Andreas, et al.
Publicado: (2023) -
Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells
por: Guo, Rong, et al.
Publicado: (2019) -
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
por: Lin, Jessica J., et al.
Publicado: (2020) -
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)